Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/175587
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQuintairos Domenech, Luis-
dc.contributor.authorColom Codina, Helena-
dc.contributor.authorMillán, Olga-
dc.contributor.authorFortuna, Virginia-
dc.contributor.authorEspinosa, Cristina-
dc.contributor.authorGuirado, Lluís-
dc.contributor.authorBudde, Klemens-
dc.contributor.authorSommerer, Claudia-
dc.contributor.authorLizana, Ana-
dc.contributor.authorLópez Púa, Yolanda-
dc.contributor.authorBrunet i Serra, Mercè-
dc.date.accessioned2021-03-23T10:12:53Z-
dc.date.available2021-03-23T10:12:53Z-
dc.date.issued2021-01-22-
dc.identifier.issn1932-6203-
dc.identifier.urihttp://hdl.handle.net/2445/175587-
dc.description.abstractPrevious results from our group and others have shown that urinary pellet expression of miR155-5p and urinary CXCL-10 production could play a key role in the prognosis and diagnosis of acute rejection (AR) in kidney transplantation patients. Here, a logistic regression model was developed using NONMEM to quantify the relationships of miR155-5p urinary expression, CXCL-10 urinary concentration and tacrolimus and mycophenolic acid (MPA) exposure with the probability of AR in adult kidney transplant patients during the early post-transplant period. Owing to the contribution of therapeutic drug monitoring to achieving target exposure, neither tacrolimus nor MPA cumulative exposure was identified as a predictor of AR in the studied population. Even though CXCL-10 urinary concentration showed a trend, its effect on AR was not significant. In contrast, urinary miR155-5p expression was prognostic of clinical outcome. Monitoring miR155-5p urinary pellet expression together with immunosuppressive drug exposure could be very useful during routine clinical practice to identify patients with a potential high risk of rejection at the early stages of the post-transplant period. This early risk assessment would allow for the optimization of treatment and improved prevention of AR.-
dc.format.extent20 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherPublic Library of Science (PLoS)-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0245880-
dc.relation.ispartofPLoS One, 2021, vol. 16, num. 1, p. e0245880-
dc.relation.urihttps://doi.org/10.1371/journal.pone.0245880-
dc.rightscc-by (c) Quintairos, Lluís et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationMarcadors bioquímics-
dc.subject.classificationFarmacocinètica-
dc.subject.classificationTrasplantament renal-
dc.subject.classificationFactors de risc en les malalties-
dc.subject.otherBiochemical markers-
dc.subject.otherPharmacokinetics-
dc.subject.otherKidney transplantation-
dc.subject.otherRisk factors in diseases-
dc.titleEarly prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec707394-
dc.date.updated2021-03-23T10:12:53Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33481955-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
707394.pdf1.31 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons